Australia's most trusted
source of pharma news
Posted 5 February 2025 PM
Vantive has officially launched as a major player in treating kidney disease, bringing with it 70 years experience from its previous incarnation as Baxter Kidney Care Segment.
The new company employs more than 23,000 people around the world and had revenues of $7.2 billion (US$4.5 billion) in 2023. In Baxter CEO Jose Almeida's swansong the business unit was sold to private equity firm Carlyle for $6.1 billion (US$3.8 billion), with 92 per cent coming in cash, which Baxter will use to pay down debt.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.